![](/wp-content/uploads/2019/03/zafgen-earnings.png)
$599
Zafgen Q4 ’18 Earnings Update; ZGN-1258 Discontinued in PWS
Yesterday, Zafgen hosted its Q4 ’18 earnings call and discussed its pathway to have FDA remove the clinical hold on ZGN-1061, its novel MetAP2 inhibitor for the treatment of T2DM. Additionally, Zafgen disclosed it has discontinued development of ZGN-1258 for the development of Prader-Willi Syndrome due to unforeseen findings in rat toxicity studies. Below are highlights and insights from the call.